Challenges and Trends in Vaccine Manufacturing - An evaluation of the technologies and process parameters needed to develop a safe, effective, and economically efficient vaccine. This article is part

ADVERTISEMENT

Challenges and Trends in Vaccine Manufacturing
An evaluation of the technologies and process parameters needed to develop a safe, effective, and economically efficient vaccine. This article is part of a special section on vaccines.


BioPharm International Supplements
Volume 24, Issue 10, pp. s3-s11

REFERENCES

1. S. Plotkin, W. Orenstein, P. Offit, Vaccines (Saunders, Philadelphia, 5th ed. 2008).

2. C. Scott, supplement to BioProcess Intl. 6 (6) s12–s18 (2008).

3. S. Fetzer, supplement to BioPharm Intl. 21 (1) s1–s6 (2008).

4. C.P. Steffy and L. Rosin, BioProcess Intl. 2 (4), s48–s57 (2004).

5. P. Holland-Moritz, BioPharm Bulletin (June 2006).

6. S. Srivastava, Vaccine World Summit March 1–3 (2011).

7. S.S. Ozturk, Cytotechnology 22, 3–16 (1996).

8. A. Heuer, The Bridge Editor's Note 36 (3) 3 (2006).

9. B. Kalbfuss et al., Jrnl. of Membrane Sci. 299, 251–260 (2007).

10. A. Karger, J. Schmidt, and T.C. Metten-leiter, Jrnl. Virol. 72, 7341–7348 (1998).

11. T. Vicente et al., Jrnl. of Membrane Sci. 311, 270–283 (2008).

12. T. Vicente et al., Gene Therapy 16, 766–775 (2009).

13. J. Tal, J Biomedical Sci. 7, 279–291 (2000).

14. WHO, Temperature Sensitivity of Vaccines, http://whqlibdoc.who.int/hq/2006/WHO_IVB_06.10_eng.pdf, accesses Sept. 6, 2011.

15. D. Chen and D. Kristensen, Expert Rev. Vaccines 8 (5), 547–557 (2009).

16. E. Boer, supplement to BioProcess Intl. 6 (10), 38–40 (2008).

17. N.W. Baylor, supplement to BioPharm Intl. 20 (8) (2007).

18. H. Pora, BioPharm Intl. 19 (6) (2006).

19. L. Leveen and S. Cox, presentation at IBC's 5th International Single-Use Applications for Biopharmaceutical Manufacturing (San Diego, 2008).

20. D. Newman and S. Walker, presentation at IBC's 5th International Single-Use Applications for Biopharmaceutical Manufacturing (San Diego, 2008).

21. G. Healy, Microbiologist 3, 28–30 (2006).

22. C. Scott, supplement to BioProcess Intl. 9, 3–42 (2010).

ACKNOWLEDGMENT

The author would like to acknowledge colleagues from Sartorius Stedim Biotech, Mahesh Prashad and Frank Meyeroltmanns for sharing their knowledge and designing the generic schemes for platform processes in vaccine manufacturing. The author appreciates the support of Dr. Uwe Gottschalk, vice-president of purification technologies at Sartorius Stedim Biotech. The author would also like to acknowledge Anurag S. Rathore, PhD, a faculty member at the Indian Institute of Delhi, India, for his editorial assistance with this paper. Rathore is a member of BioPharm International's Editorial Advisory Board and the author of the journal's series on the Elements of Biopharmaceutical Production.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here